What is the recommended management for immune checkpoint inhibitor‑induced interstitial lung disease?

Management of Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease

For immune checkpoint inhibitor-induced ILD, management is grade-dependent: hold ICIs for Grade 1 with close monitoring, initiate corticosteroids (1-2 mg/kg/day prednisone) and hold ICIs for Grade 2, permanently discontinue ICIs and hospitalize for Grade 3-4 with high-dose IV methylprednisolone (1-2 mg/kg/day), escalating to additional immunosuppressants if no improvement within 48 hours. 1

Grade-Based Management Algorithm

Grade 1 (Asymptomatic, <25% lung involvement)

• Hold ICI or proceed with very close monitoring 1
• Obtain pulmonary and infectious disease consultations 2
• Monitor weekly with:
  • History and physical examination
  • Pulse oximetry
  • Consider chest imaging (CXR or CT) 1
• Repeat chest imaging in 3-4 weeks or sooner if symptoms develop 1
• Resume ICI only if radiographic improvement or resolution documented 1
• If no improvement or progression occurs, escalate to Grade 2 management 2, 1

Grade 2 (Symptomatic, 25-50% lung involvement, limiting instrumental ADLs)

• Hold ICI until clinical improvement to Grade 1 1
• Initiate prednisone 1-2 mg/kg/day (or IV methylprednisolone equivalent) 2, 1
• Consider hospitalization with pulmonary and infectious disease consultations 2
• Perform bronchoscopy with bronchoalveolar lavage; consider transbronchial biopsies for atypical lesions 2, 1
• Rule out infection with comprehensive workup:
  • Nasal swab, sputum culture
  • Blood and urine cultures
  • Consider empiric antibiotics if infection remains in differential 1
• Monitor at least weekly with history, physical exam, pulse oximetry, and radiologic imaging 1
• If no clinical improvement after 48-72 hours of corticosteroids, escalate to Grade 3 management 2, 1
• If symptoms improve to ≤Grade 2, start slow steroid taper over 4-6 weeks 2, 1
• Consider drug rechallenge only if symptoms and imaging abnormalities completely resolve 2

Grade 3 (Severe symptoms, >50% lung involvement, oxygen required)

• Permanently discontinue ICI 2, 1
• Hospitalize; consider ICU-level care 2, 1
• Initiate IV methylprednisolone 1-2 mg/kg/day 1
• Pulmonary consultation for bronchoscopy with BAL; consider biopsies if patient can tolerate 2, 1
• Empiric antibiotics may be considered 1
• If no improvement after 48 hours, add additional immunosuppressive agent: 2, 1
  • Infliximab, OR
  • Mycophenolate mofetil IV, OR
  • IVIG, OR
  • Cyclophosphamide
• If clinical improvement occurs, reduce corticosteroids to 1 mg/kg/day and taper slowly over 4-6 weeks 2, 1
• Drug rechallenge: Consider only on case-by-case basis after risk/benefit discussion with patient, and only if complete resolution of symptoms and imaging abnormalities 2

Grade 4 (Life-threatening respiratory compromise, intubation)

• Permanently discontinue ICI 2, 1
• Initiate IV methylprednisolone 2 mg/kg/day 2
• ICU admission with mechanical ventilation support as needed 1
• Pulmonary consultation for bronchoscopy with BAL and biopsies if patient can tolerate 2, 1
• Day 2-3 assessment: 2
  • If no clinical improvement: Add infliximab, cyclophosphamide, mycophenolate mofetil, or IVIG
  • If clinical improvement: Reduce to 1 mg/kg/day and taper over >2 months
• Drug rechallenge: Absolutely contraindicated for Grade 4 2

Critical Supportive Measures

Prophylaxis Requirements (All Grades ≥2)

• PCP prophylaxis: For patients receiving ≥20 mg methylprednisolone equivalent for ≥4 weeks 2
• GI prophylaxis: Proton pump inhibitor therapy for all patients with Grade 2-4 pneumonitis receiving steroids 2
• Bone protection: Calcium and vitamin D supplementation with prolonged steroid use 2
• TB screening: T-spot testing before initiating anti-TNF therapy (infliximab) 2

Key Clinical Pitfalls

Delayed recognition is associated with higher severity and less reversibility, resulting in residual fibrosis. 3 The 2021 ASCO guidelines emphasize that early diagnosis and prompt intervention are critical for optimal outcomes 1.

High-Risk Populations Requiring Enhanced Surveillance

• Preexisting ILD: 3-fold increased risk of ICI-ILD (OR 3.23) and higher mortality 3, 4, 5
• Severe emphysema (E score ≥3): 31.3% incidence vs 14.7% in mild emphysema 6
• Extensive interstitial lung abnormalities: 42.3% incidence vs 9.9% in limited ILA 6
• Prior thoracic radiotherapy: Independent risk factor (OR 4.10) 6
• NSCLC patients: Higher treatment-related deaths from pneumonitis compared to other tumor types 1

Insidiously Progressive ICI-ILD

A particularly dangerous pattern involves unnoticed development with insidious progression leading to respiratory failure, often with non-organizing pneumonia pattern and weak corticosteroid response 7. This subtype may have ICI administered for 6+ cycles between when ILD becomes retrospectively recognizable and when treatment is discontinued, with gradual increases in CRP and ILD extent 7. Early discontinuation upon recognition is critical to prevent fatal outcomes 7.

Radiologic Patterns

Five distinct subtypes have been identified: COPD-like, ground-glass opacities, hypersensitivity type, interstitial type, and pneumonitis not otherwise specified 1. Ground-glass opacities or patchy nodular infiltrates, predominantly in lower lobes, are most common 1.

Steroid-Refractory Disease

Approximately 20% of cases do not improve after >48 hours of corticosteroid therapy 1. The evidence for second-line immunosuppressants comes from two large retrospective studies, with options including infliximab, mycophenolate mofetil, IVIG, or cyclophosphamide 1.

Prognosis Considerations

Paradoxically, patients who develop ICI-ILD often have better tumor responses and survival outcomes 8. In one study, ILD patients had 63% ORR vs 22% in non-irAE patients, with median PFS of 15.9 months vs 3.3 months 8. However, this benefit is negated by fatal ICI-ILD, emphasizing the critical importance of early recognition and appropriate management 7.